title: MT-103 Micromet/MedImmune.
abstract: Micromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia.
authors.affiliation: Paterson Institute for Cancer Research, Department of Medical Oncology, Wilmslow Road, Manchester M204BX, UK. Echeadle@picr.man.ac.uk
authors.forename: Eleanor J
authors.initials: EJ
authors.lastname: Cheadle
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D004345:Drug Industry; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D013329:Structure-Activity Relationship
chemical_list: D018033:Antibodies, Bispecific; C510808:blinatumomab